Skip to main content

Table 1 Parameters indicative of Leishmania major amastigote viability and infectivity to J774A.1 in the crude ES, fractionated larval ES and Glucantime treatments

From: Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions

Treatment Dosage (μg/ml) Infected cells (%) Viability of amastigotes (%) Parasite load Survival index
Control 0 85.37 ± 3.58 100 ± 0.00 3.19 ± 0.01 270.9 ± 1.15
Crude ES 150 41.66 ± 1.28* 30.27 ± 1.93* 1.97 ± 0.02* 82.23 ± 2.35*
  300 32.00 ± 2.43* 20.58 ± 2.74* 1.75 ± 0.05* 53.72 ± 2.44*
> 10-kDa ES 150 58.33 ± 2.75 49.90 ± 2.71* 2.28 ± 0.03 132.99 ± 2.01*
  300 51.00 ± 1.55* 39.46 ± 3.42* 2.10 ± 0.01* 107.33 ± 2.51*
< 10-kDa ES 150 62.66 ± 2.38 59.93 ± 2.86* 2.60 ± 0.10 162.73 ± 2.10*
  300 55.00 ± 3.10* 49.02 ± 3.53* 2.42 ± 0.00* 133.21 ± 2.38*
Glucantime 50 39.66 ± 2.08* 28.54 ± 0.56* 1.96 ± 0.07* 77.67 ± 1.53*
  100 30.85 ± 1.53* 15.51 ± 1.12* 1.68 ± 0.02* 51.01 ± 2.01*
  1. *P < 0.05 (significantly different from the negative control)